Recent Quotes View Full List My Watchlist Create Watchlist Indicators DJI Nasdaq Composite SPX Gold Crude Oil Hydroworld Market Index Markets Stocks ETFs Tools Overview News Currencies International Treasuries Regeneron Pharmaceuticals (NQ: REGN ) 1,138.81 -7.94 (-0.69%) Streaming Delayed Price Updated: 4:00 PM EDT, Sep 18, 2024 Add to My Watchlist Quote Overview Detailed Quote Charting Historical Prices News All News News Headlines Press Releases Research Quarterly Reports Insider Filings Other Filings Price and Volume Detailed Quote Volume 328,267 Open 1,151.32 Bid (Size) 1,138.82 (1) Ask (Size) 1,196.00 (1) Prev. Close 1,146.75 Today's Range 1,137.64 - 1,156.40 52wk Range 769.19 - 1,211.20 Shares Outstanding 91,779,465 Dividend Yield N/A Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year Top News More News Dupixent® (dupilumab) Approved in the U.S. as First and Only Treatment for Adolescents with Chronic Rhinosinusitis with Nasal Polyps (CRSwNP) September 13, 2024 From Regeneron Pharmaceuticals, Inc. Via GlobeNewswire Time To Invest And Or Trade In Bio-Tech Stocks? September 13, 2024 Biotechnology stocks and biotech exchange-traded funds ETFs once played a significant role in growth equity rallies, but today it seems like those days are in the past. Will an interest rate cut help... Via Talk Markets Topics ETFs Performance YTD +25.84% +25.84% 1 Month -4.85% -4.85% 3 Month +9.04% +9.04% 6 Month +17.77% +17.77% 1 Year +36.10% +36.10% More News Read More Biotech Breakout: Stocks for Your Watchlist September 12, 2024 Via MarketBeat Topics ETFs Competitor Analysis: Evaluating Regeneron Pharmaceuticals And Competitors In Biotechnology Industry September 11, 2024 Via Benzinga $1000 Invested In This Stock 5 Years Ago Would Be Worth $4,000 Today September 10, 2024 Via Benzinga Beyond The Numbers: 20 Analysts Discuss Regeneron Pharmaceuticals Stock September 09, 2024 Via Benzinga Evaluating Regeneron Pharmaceuticals Against Peers In Biotechnology Industry August 27, 2024 Via Benzinga Sanofi, Regeneron Drug Dupixent Shows Successful Treatment Of Patients With Inflammatory Skin Disease September 11, 2024 Via Benzinga MAIA Biotechnology's Phase 2 Study Of THIO In Non-Small Cell Lung Cancer Shows Positive Interim Survival Benefits September 11, 2024 Via News Direct EYLEA HD® (aflibercept) Injection 8 mg Data at EURETINA Reinforce Long-term Durability, Sustained Fluid Control and Safety Profile September 11, 2024 From Regeneron Pharmaceuticals, Inc. Via GlobeNewswire Prediction: These 2 Companies Will Split Their Stocks by 2027 September 11, 2024 Via The Motley Fool What Analysts Are Saying About Regeneron Pharmaceuticals Stock August 23, 2024 Via Benzinga If You Invested $1000 In This Stock 20 Years Ago, You Would Have $130 Thousand Today August 20, 2024 Via Benzinga Dupixent® (dupilumab) Phase 3 Trial Confirms Significant Improvements in Itch and Hives for Patients with Chronic Spontaneous Urticaria (CSU) September 11, 2024 From Regeneron Pharmaceuticals, Inc. Via GlobeNewswire Dupixent® (dupilumab) Is the First and Only Biologic to Achieve Significant Improvements in Disease Remission and Symptoms in Bullous Pemphigoid (BP) Positive Pivotal Trial September 11, 2024 From Regeneron Pharmaceuticals, Inc. Via GlobeNewswire Libtayo® (cemiplimab) Demonstrates Durable Survival Benefit at Five Years in Advanced Non-small Cell Lung Cancer September 09, 2024 From Regeneron Pharmaceuticals, Inc. Via GlobeNewswire Regeneron to Highlight Progress Across Its Differentiated Oncology Portfolio and Pipeline at WCLC and ESMO September 09, 2024 From Regeneron Pharmaceuticals, Inc. Via GlobeNewswire Prediction: These 2 Cathie Wood Stocks Could Crush the Market Through 2030 September 05, 2024 Via The Motley Fool Biotech And Life Science Sector Update Summer Of 2024 August 29, 2024 Via Talk Markets Ordspono™ (odronextamab) Approved in the European Union for the Treatment of Relapsed/Refractory Follicular Lymphoma and Diffuse Large B-cell Lymphoma August 26, 2024 From Regeneron Pharmaceuticals, Inc. Via GlobeNewswire Latest Dupixent® (dupilumab) and Itepekimab Data at ERS Highlight Scientific Innovation and Leadership in Respiratory Diseases August 26, 2024 From Regeneron Pharmaceuticals, Inc. Via GlobeNewswire 10 Bagger Stocks: Can You Find One? August 23, 2024 Via Talk Markets Regeneron Faces Setback With FDA Rejection Of Blood-Cancer Treatment August 20, 2024 Via Benzinga Exposures Product Safety Regeneron Provides Update on Biologics License Application for Linvoseltamab August 20, 2024 From Regeneron Pharmaceuticals, Inc. Via GlobeNewswire Biotech Bull Market: 3 Ways To Play It August 20, 2024 Via Talk Markets Topics Economy Exposures Interest Rates Data & News supplied by www.cloudquote.io Stock quotes supplied by Barchart Quotes delayed at least 20 minutes. By accessing this page, you agree to the following Privacy Policy and Terms and Conditions.